Home page A B C D E F G H I K L M N O P Q R S T U V W X Y Z

Zolpidem Use During Pregnancy

Udocheals.orgAmbien category
7.19.2017 | Logan Miers
Ambien category
Zolpidem Use During Pregnancy

Pregnancy Category C Risk cannot be ruled out.

Approval History Calendar Drug history at FDA More FDA updates.

Availability Rx Prescription only.

CSA Schedule 4 Some potential for abuse.

-Effects on the neonate (e.g., hypothermia, hypotonia, moderate respiratory depression) can be expected if this drug is administered during the late phase of pregnancy or during labor. AU TGA pregnancy category: B3 US FDA pregnancy category: C Comments: -Advise a female patient of childbearing potential to stop using this drug if she intends to become or suspects that she is pregnant. US: Use during pregnancy only if the potential benefit outweighs the potential risk to the fetus. See references. AU, UK: Safety in pregnancy has not been established; avoid use in pregnancy, especially during the first trimester.

Subscribe to receive notifications whenever new articles are published.

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

US: Use with caution in nursing mothers. AU, UK: Use in nursing mothers is not recommended. See references. Excreted into human milk: Yes Comments: Due to the low levels of this drug in breastmilk and its short half-life, amounts ingested by nursing infants are small and would not be expected to cause any adverse effects in these infants.

Zolpidem is also known as: Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist.

Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist. Multum Information Services, Inc. This material does not endorse drugs, diagnose patients, or recommend therapy. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect.

In animals, administration of this drug during the latter part of pregnancy and throughout lactation produced decreased offspring growth and survival at all but the lowest dose tested. Breastmilk collected 3 hours after a single oral 20 mg dose of this drug was administered to 5 nursing mothers (who were 3 to 4 days postpartum) showed the breastmilk contained between 0.004% to 0.019% of the maternal dosage; the drug was undetectable (less than 0.5 mcg/L) in the breastmilk 13 and 16 hours after the dose.

We comply with the HONcode standard for trustworthy health information - verify here.

Infants born to mothers who took benzodiazepines or benzodiazepine-like agents chronically during the latter stages of pregnancy may be at risk for developing physical dependence and withdrawal symptoms in the postnatal period. Cases of severe neonatal respiratory depression have been reported when this drug was used at the end of pregnancy, especially when used with other central nervous system (CNS) depressants. Animal studies have revealed no evidence of teratogenicity or fertility impairment, but adverse effects including incomplete fetal skeletal ossification and increased embryo-fetal death have occurred. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans. Additionally, neonatal flaccidity also has been reported in infants born to mothers who received sedative/hypnotic drugs during pregnancy. AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed.

To view content sources and attributions, please refer to our editorial policy. Data sources include Micromedex (updated June 2nd, 2017), Cerner Multum (updated June 5th, 2017), Wolters Kluwer (updated June 6th, 2017) and others. provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.

Ambien category